Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Measurement of Bioavailability: Pharmacokinetic Methods01:30

Measurement of Bioavailability: Pharmacokinetic Methods

Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
Drug Dissolution: Requirements and Profile Comparison01:14

Drug Dissolution: Requirements and Profile Comparison

The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Influencing Factors01:20

Modified-Release Drug Delivery Systems: Influencing Factors

Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Modified-Release Drug Delivery Systems: Drug Release Characteristics01:22

Modified-Release Drug Delivery Systems: Drug Release Characteristics

Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Hearing loss: An unmet need in oncology care.

Journal of geriatric oncology·2026
Same author

Ten-Year Cost Projections for Medicare Beneficiaries 65 Years or Older With HIV.

JAMA network open·2026
Same author

Postacute COVID-19 Symptoms and Health Care Utilization and Spending Among Traditional Medicare Beneficiaries.

JAMA network open·2026
Same author

Racial and ethnic disparities in GLP-1 prescriptions among veterans with obesity across direct and community care settings.

Health affairs scholar·2026
Same author

Chronic Conditions and Mortality in Medicare Beneficiaries Before and After the COVID-19 Pandemic.

JAMA network open·2026
Same author

Long-Acting Injectable Antiretroviral Therapy in Medicare-Enrolled Adults With HIV.

JAMA network open·2026

相关实验视频

Updated: Jul 9, 2026

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

药物释放支架的晚期流失的光径和二进制缩比较药物释放支架.

Laura Mauri1, E John Orav, Richard E Kuntz

  • 1Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02116, USA. lmauri1@partners.org

Circulation
|June 22, 2005
PubMed
概括

晚期失去光线直径是冠状动脉支架的复原风险的可靠预测指标. 这种血管学测量比传统的复原率提供了更大的统计能力,特别是在新的药物释放支架上.

科学领域:

  • 心血管研究研究心血管研究
  • 干预心脏病学 干预心脏病学
  • 生物医学工程 生物医学工程

背景情况:

  • 冠状动脉复缩率在药物释放支架下显著下降.
  • 早期的支架评估通常使用替代连续终点.
  • 这些替代终点的概括性和力量需要进行系统的检查.

研究的目的:

  • 为了评估晚期光线损失和复缩概率之间的关系.
  • 为了比较晚期光线损失与二进制复缩的统计力.
  • 评价晚期光线损失作为新支架试验的终点.

主要方法:

  • 从22个已发表的支架试验中分析了晚期光线损失数据.
  • 包括裸金属,药物排泄和小血管支架.
  • 晚期损失差异和二进制复原率之间的功率比较.

主要成果:

  • 观察到平均晚期损失及其标准偏差之间存在线性关系,这与支架类型或血管直径无关.
  • 增加晚期光线损失单调地与更高的复原风险有关.
  • 晚期光线损失在检测治疗效果方面表现得显著更强,与二进制复原相比.

结论:

更多相关视频

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

相关实验视频

Last Updated: Jul 9, 2026

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model
09:46

Imaging In-Stent Restenosis: An Inexpensive, Reliable, and Rapid Preclinical Model

Published on: September 14, 2009

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access
05:04

Implantation of Human-Sized Coronary Stents into Rat Abdominal Aorta Using a Trans-Femoral Access

Published on: November 19, 2020

  • 晚期光线损失是一种可概括和强大的血管造影终点.
  • 它与各种支架类型的复缩风险有着强烈而单调的关系.
  • 晚期流光损失对于新药释放支架的早期试验特别有价值.